![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection
|
|
|
Reported by Jules Levin
10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico
![0724191](../images/072519/072519-9/0724191.gif)
![0724192](../images/072519/072519-9/0724192.gif)
![0724193](../images/072519/072519-9/0724193.gif)
![0724194](../images/072519/072519-9/0724194.gif)
![0724195](../images/072519/072519-9/0724195.gif)
![0724196](../images/072519/072519-9/0724196.gif)
![0724197](../images/072519/072519-9/0724197.gif)
![0724198](../images/072519/072519-9/0724198.gif)
![0724199](../images/072519/072519-9/0724199.gif)
![07241910](../images/072519/072519-9/07241910.gif)
![07241911](../images/072519/072519-9/07241911.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|